# Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

> **NCT03828201** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Boston University** · enrollment: 271 (actual)

## Conditions studied

- Tuberculosis, Multidrug-Resistant

## Interventions

- **DRUG:** Delamanid
- **DRUG:** Levofloxacin
- **DRUG:** Bedaquiline
- **DRUG:** Clofazimine
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT03828201
- **Lead sponsor:** Boston University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-07
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828201, "Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03828201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*